Lung Cancer Clinical Trial
Official title:
Evaluation of the Benefits of Oral Metronomic Cyclophosphamide in Combination With Standard Cisplatin-etoposide Based Chemotherapy for Squamous Cell Lung Carcinoma
Treatment of locally advanced and metastatic squamous cell carcinoma of the lung involves
the use of chemotherapy as the therapeutic mainstay. Platinum-etoposide regimens (such as
cisplatin-etoposide) are the most commonly used chemotherapeutic regimen, which is delivered
intravenously in the standard three-weekly intervals.
Recent interest in oral metronomic chemotherapy has arisen, especially due to its beneficial
effects in delaying disease progression among heavily pre-treated patients with various
malignancies.
This study attempts to combine the use of metronomic chemotherapy concurrently during
standard intravenous chemotherapy.
Adenocarinoma and squamous cell carinoma are the two major types of non-small cell lung
carcinoma. While patients with adenocarcinoma of the lung have the feasibility of treatment
with tyrosine kinase inhibitors, the patients with squamous cell carcinoma can only be
treated with standard chemotherapy due to the ineffectiveness of tyrosine kinase inhibitors.
Thus, the current standard is to treat patients of squamous cell lung cancers with standard
intravenous chemotherapy, which is mostly delivered once in three weeks.
Metronomic chemotherapy, meaning the delivery of low doses of chemotherapy, often by an oral
approach, on a daily basis so as to maintain a low but definite level of the chemotherapy
has received great interest in recent times due to its beneficial effects in terms of
extending progression free survival among patients of various malignancies, even after
failure with previous conventional therapies. Metronomic chemotherapy is proposed to be
active by alternate mechanisms, such as the predominant anti-angiogenic effect, in contrast
to the cytotoxic and genotoxic effects of standard chemotherapy.
Metronomic chemotherapy with oral cyclophosphamide has been shown to extend progression free
survival when used as a single agent in various malignancies. Given the fact that
progression after varying time spans is a rule (rather than the exception) among patients of
squamous cell lung cancer being treated with conventional chemotherapy, we have intended to
combine the use of oral metronomic chemotherapy given concurrently with standard intravenous
cisplatin-etoposide based chemotherapy. We intend to observe a prolongation of progression
free survival.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
| Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
| Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
| Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
| Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
| Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|